Azafaros for Patients
Azafaros develops treatments for Lysosomal Storage Disorders by combining disease expertise, therapy development experience, and the latest scientific insights.
azafaros.comCrawled Oct 30, 2026
Azafaros develops treatments for Lysosomal Storage Disorders by combining disease expertise, therapy development experience, and the latest scientific insights.
Lysosomes are organelles that break down molecules like lipids, sugars, and proteins using enzymes, supporting cellular function.
Lysosomal storage diseases (LSDs) are a group of over 70 rare genetic metabolic disorders caused by lysosomal dysfunction, most inherited as autosomal recessive traits, affecting 1 in 5,000 live births.
In recent years, researchers have discovered several enzymes that may serve as potential targets for the treatment of neurodegenerative lysosomal storage disorders.
Azafaros CEO Stefano Portolano discussed in depth the promise of brain-penetrant small molecules, such as nizubaglustat, and their potential to change the lives of rare d
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustat Recruitment completed in Phase 3 registrational study in patients with late-infantile and juv
Leiden, Netherlands, June 15, 2026 – Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addr
Patient family documentary: A dedicated father’s journey in seeking hope in clinical trials in Brazil for his son, Facundo, who suffers from Tay-Sachs di
Operating Partner at Forbion Capital Partners
Stefano Portolano, Azafaros’ CEO since 2021, has over 20 years of experience in orphan disease and specialty drugs, including leadership roles in commercial, market access, and medical affairs at Ultragenyx Pharmaceuticals and Celgene.
Azafaros, a clinical-stage company founded in 2018, focuses on rare genetic disease mechanisms, building on research by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and Amsterdam UMC.
Azafaros’ clinical candidate, nizubaglustat, is an orally available azasugar designed to treat the central nervous system by targeting glycosphingolipid metabolism in key disease pathways.
Azafaros B. V. Address: Azafaros B.V. J.H. Oortweg 21 2333 CH Leiden The Netherlands